Overview

Comparison of Two Dosage Strengths of Transdermal Fentanyl Versus Transdermal Buprenorphine and Placebo in Acute Pain Models in Healthy Volunteers.

Status:
Completed

Trial end date:
2005-01-01

Target enrollment:

Participant gender:

Summary

The primary objective of this pilot trial is to identify pain model(s) which allow(s) to compare and differentiate the analgesic effects between transdermal fentanyl 25Âµg/h, transdermal fentanyl 12Âµg/h and placebo in a dose dependent way. The second objective is to compare the effects of transdermal buprenorphine 35Âµg/h in these models with the effect of the two transdermal fentanyl dosages. Therefore four different treatments are given; all treatments will be by means of a patch that is attached to the back for 72 hours.

Phase:

Phase 1

Details

Lead Sponsor:

Janssen-Cilag A.G., Switzerland

Treatments:

Buprenorphine
Fentanyl
Naloxone